|
|
|
|
|
非在研适应症- |
最高研发阶段批准上市 |
|
首次获批日期2022-10-31 |
|
|
|
|
|
非在研适应症- |
最高研发阶段批准上市 |
|
首次获批日期2022-03-28 |
|
|
|
|
|
非在研适应症- |
最高研发阶段批准上市 |
|
首次获批日期2021-08-06 |
A multi-center, prospective, longitudinal cohort study of Chlamydia trachomatis infection and reinfection in adults aged 18 to 29 years.
A randomized, placebo-controlled, sequential, participant- and Investigator-masked Phase 1 study to assess the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics ( PD) of ascending single and multiple doses of SAR446422 in female and male healthy participants 18 to 55 years of age
A randomized, double-blind, placebo-controlled, phase 1, single centre, First-in-human, two-part study to investigate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of single (SAD17442) and multiple (MAD17443) ascending, subcutaneous doses of SAR444559 in healthy adult participants.
100 项与 Sanofi-Aventis Australia Pty Ltd. 相关的临床结果
0 项与 Sanofi-Aventis Australia Pty Ltd. 相关的专利(医药)
100 项与 Sanofi-Aventis Australia Pty Ltd. 相关的药物交易
100 项与 Sanofi-Aventis Australia Pty Ltd. 相关的转化医学